Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q3 2020 Results Conference Call November 4, 2020 8:00 AM ET Company Participants Tom Bures - VP, Finance Steve Yoder - President and CEO Hitto Kaufmann - Chief Scientific Officer Shane Olwill - SVP and Head, Translational Science Conference Call Participants Joseph Thome - Cowen and Company Madhu Kumar - Baird Jonathan Miller - Evercore ISI Matt Phipps - William Blair Sharon Ofer - Sphera Fund Operator Greetings, and welcome to the Pieris Pharmaceuticals Third Quar ...

1 A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive Malignancies Authors: Sarina Piha-Paul1, Johanna Bendell2, Anthony Tolcher3, Sara Hurvitz4, Anuradha Krishnamurthy5, Anthony El-Khoueiry6, Amita Patnaik7, Rachna Shroff8, Anne Noonan9, Paula Pohlmann10, Noah Hahn11, Marc Matrana12, Markus Zettl13, Kayti Aviano13, Lynn Mar13, Patrick Jolicoeur13, Shane Olwill13, Ingmar Bruns13, Geoffrey Ku14 1The University of Texas MD Anderson Cancer Center, Texas, ...

Pieris Pharmaceuticals, Inc. (PIRS) Q2 2020 Earnings Conference Call August 10, 2020 8:00 AM ET Company Participants Tom Bures - Vice President of Finance Steve Yoder - President and Chief Executive Officer Ingmar Bruns - Senior Vice President and Head of Clinical Development Hitto Kaufmann - Senior Vice President and Chief Scientific Officer Shane Olwill - Senior Vice President and Head of Translational Science Conference Call Participants Jonathan Miller - Evercore ISI Madhu Kumar - Robert W. Baird & Co. ...

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2020 Earnings Conference Call May 11, 2020 8:00 AM ET Â Company Participants Tom Bures – Vice President of Finance Steve Yoder - President and Chief Executive Officer Ingmar Bruns – Senior Vice President and Head of Clinical Development Hitto Kaufmann - Senior Vice President and Chief Scientific Officer Shane Olwill – Senior Vice President and Head of Translational Science Conference Call Participants Jonathan Miller – Evercore ISI Chang Liu – Jefferies Madhu Ku ...

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2019 Earnings Conference Call March 12, 2020 8:00 AM ET Company Participants Thomas Bures - Principal Financial & Accounting Officer & Treasurer Stephen Yoder - CEO, President & Director Shane Olwill - SVP & Head, Translational Science Ingmar Bruns - SVP & Head, Clinical Development Conference Call Participants Jonathan Miller - Evercore ISI Pamela Barendt - Cowen and Company Jennifer Teubl - Robert W. Baird & Co. Biren Amin - Jefferies Matthew Phipps - William ...

INVESTOR PRESENTATION JANUARY 2020 Forward Looking Statements This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward- looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods and our business and product development plans, including the advanc ...

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q3 2019 Results Earnings Conference Call November 11, 2019 8:00 AM ET Company Participants Thomas Bures - Principal Financial & Accounting Officer and Treasurer 2 Stephen Yoder - CEO, President Ingmar Bruns - VP, Clinical Development Shane Olwill - VP, Head:Development Conference Call Participants John Miller - Evercore ISI Joe Pantginis - H.C. Wainwright Madhu Kumar - Robert W. Baird Chris Shibutani - Cowen Biren Amin - Jeffries Umer Raffat - Evercore Matt Phipps ...

| --- | --- | --- | |-----------------------------|-------|-------| | | | | | | | | | | | | | | | | | INVESTOR | | | | | | | | | | | | | | | | | | | | PRESENTATION OCTOBER 2019 | | | Forward Looking Statements This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward- looking statements. Such forward-looking state ...

| --- | --- | --- | |----------------------------|-------|-------| | | | | | | | | | | | | | INVESTOR | | | | | | | | | | | | | | | | | | | | | | | | PRESENTATION AUGUST 2019 | | | Forward Looking Statements This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward- looking statements. Such forward-looking stateme ...

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q2 2019 Results Conference Call August 1, 2019 8:00 AM ET Company Participants Allan Reine – Chief Financial Officer Steve Yoder – President and Chief Executive Officer Lou Matis – Senior Vice President and Chief Development Officer Conference Call Participants Jonathan Miller – Evercore ISI Biren Amin – Jefferies Matthew Phipps – William Blair Joe Pantginis – H.C. Wainwright Pam Barendt – Cowen Operator Good morning and welcome to the Pieris Pharmaceuticals Second ...